Axogen, Inc. (AXGN)
NASDAQ: AXGN · Real-Time Price · USD
18.99
+0.84 (4.63%)
Mar 25, 2025, 4:00 PM EST - Market closed
Axogen Revenue
In the year 2024, Axogen had annual revenue of $187.34M with 17.81% growth. Axogen had revenue of $49.41M in the quarter ending December 31, 2024, with 15.10% growth.
Revenue (ttm)
$187.34M
Revenue Growth
+17.81%
P/S Ratio
4.49
Revenue / Employee
$414,465
Employees
452
Market Cap
842.09M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 187.34M | 28.33M | 17.81% |
Dec 31, 2023 | 159.01M | 20.43M | 14.74% |
Dec 31, 2022 | 138.58M | 11.23M | 8.81% |
Dec 31, 2021 | 127.36M | 15.06M | 13.41% |
Dec 31, 2020 | 112.30M | 5.59M | 5.24% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
AXGN News
- 4 weeks ago - Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Axogen, Inc. To Host Analyst & Investor Day on March 4th - GlobeNewsWire
- 6 weeks ago - Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025 - GlobeNewsWire
- 2 months ago - Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Axogen: Well Placed To Capitalize Growth At Higher Multiples - Seeking Alpha
- 4 months ago - Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 months ago - Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft® - GlobeNewsWire
- 8 months ago - Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript - Seeking Alpha